DoW Toxic Exposures Clinical Trial Award

The DoW Toxic Exposures Clinical Trial Award supports the advancement, execution, and analysis of clinical trials to prevent, treat, or manage symptoms, diseases, or conditions associated with military-related toxic exposures. The award includes a Partnering Principal Investigator Option to encourage collaborations between clinicians and research scientists. Applications should address at least one of the FY26 TERP program goals and topic areas, including predicting and preventing adverse effects, understanding clinical signs and symptoms, and developing new therapeutics. The award has a maximum period of performance of 4 years and a total cost cap of $4.5M. • Key features of the award include the requirement for preliminary data, a partnering PI option, and a focus on clinical trials with significant impact on patient care. • Eligible applicants include extramural and intramural U.S. Department of War organizations, as well as foreign and domestic organizations. • The application process involves a pre-application submission, followed by an invitation to submit a full application.